Accueil   Diary - News   All news Sensorion and Novasep announce signature of a gene therapy product development and manufacturing agreement

Sensorion and Novasep announce signature of a gene therapy product development and manufacturing agreement

 

 

    • Agreement covers the development and manufacturing of AAV vectors, a key step for Sensorion’s gene therapy programs
    •  Agreement secures drug product development and manufacturing capacity for the Company’s Otoferlin program
    •  Gene therapy could revolutionize the treatment of genetic inner ear disorders

 

Montpellier and Lyon, October 27, 2020 - 7:30 AM CET - Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, and Novasep, a leading supplier of services and technologies for the life sciences industry, announce the signature of an agreement for the manufacturing of adeno-associated virus (AAV) vectors. The agreement covers the gene therapy program targeting OTOF (OTOF-GT), the gene encoding the otoferlin protein. Mutations in OTOF lead to severe or profound congenital hearing loss.

 

 

Read the press release